2,4-Diamino-5-methyl-5,6,7,8-tetrahydro-chinazolin | 90649-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,4-Diamino-5-methyl-5,6,7,8-tetrahydro-chinazolin
• 英文别名: 5-Methyl-2,4-diamino-5,6,7,8-tetrahydro-chinazolin；5-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine；5-Methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
• CAS: 90649-10-8
• 化学式: C₉H₁₄N₄
• 分子量: 178.237
• InChiKey: QIMGVPQCIUVTKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION<br/>[FR] COMPOSÉS DESTINÉS À LA RÉDUCTION DE LA PRODUCTION DE BETA-AMYLOÏDES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011014535A1

  公开（公告）日：2011-02-03

  The present disclosure provides a series of compounds of the formula (I) which modulate β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production.

  本公开提供了一系列化合物的公式(I)，这些化合物调节β-淀粉样肽(β-AP)的产生，并在治疗阿尔茨海默病和其他受β-淀粉样肽(β-AP)产生影响的疾病中有用。
• COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
  申请人：Boy Kenneth M.

  公开号：US20120028994A1

  公开（公告）日：2012-02-02

  The present disclosure provides a series of compounds of the formula (I) which modulate β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production.

  本公开提供一系列公式(I)的化合物，可调节β-淀粉样肽（β-AP）的产生，并在治疗阿尔茨海默病和其他受β-淀粉样肽（β-AP）产生影响的疾病中有用。
• COMPOUNDS FOR THE REDUCTION OF -AMYLOID PRODUCTION
  申请人：Bristol-Myers Squibb Company

  公开号：EP2459197A1

  公开（公告）日：2012-06-06
• [EN] NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES QUINOLINE, TETRAHYDROQUINAZOLINE ET PYRIMIDINE, PROCEDES DE TRAITEMENT EN LIAISON AVEC L'UTILISATION DE CES DERNIERS
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087669A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.